secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0000950170-23-025898
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara CFO resigns; CEO Hoffman takes interim CFO role; expects VAL-083 data by Q4 2023
--------------------------------------------------------------------------------

- Scott Praill resigned as CFO effective May 31, 2023; will consult for 2 months at $5,000/month.
- CEO Robert Hoffman appointed interim CFO (retaining CEO/Chairman roles), effective June 1, 2023.
- Hoffman voluntarily reduced base salary by $60,000 indefinitely; granted 59,800 RSUs vesting June 1, 2024.
- Company expects results of GBM AGILE study for VAL-083 before end of Q4 2023.
- Expense reductions extend projected cash runway through anticipated data readout date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023025898/0000950170-23-025898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023025898/ktra-20230530.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-025898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer